VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference.

Presentation Details: Date: Monday, February 11, 2019 Time: 3:30pm ET Location: New York Marriott Marquis (Gramercy room)

About VenatoRx Pharmaceuticals, Inc.

VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. VenatoRxs lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. For more information, please visit


Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Heather Hunter
Vice President, Communications
Pharmaceuticals, Inc.
[email protected]